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Abstract
We have previously shown that the administration of low doses of insulin-like growth factor-I (IGF-I) to CCl4-cirrhotic
rats improves liver function and reduces fibrosis. To better understand the mechanisms behind the hepatoprotective effects
of IGF-I, and to identify those genes whose expression is affected in cirrhosis and after IGF-1 treatment, we have performed
differential display of mRNA analysis by means of polymerase chain reaction (PCR) in livers from control and CCl4-cirrhotic
rats treated or not with IGF-I. We have identified 16 genes that were up- or down-regulated in the cirrhotic liver. IGF-I treat-
ment partially normalized the expression of eight of these genes, including serine proteinase inhibitors such as serpin-2 and
alpha-1-antichymotripsin, alpha-1-acid glycoprotein, and alpha-2u-globulin. Additionally, we show that IGF-I enhanced the
regenerative activity in the cirrhotic liver, as determined by the increased expression of the proliferating cell nuclear antigen
(PCNA). Finally, IGF-I treatment partially restored the expression of growth hormone receptor (GHR) and the levels of global
genomic DNA methylation, which are reduced in human and experimental cirrhosis. Taken together, our observations confirm
the hepatoprotective effects of IGF-I, and suggest that this action can be exerted in part through the normalization of liver
gene expression, growth hormone (GH) responsiveness and global genomic DNA methylation. © 2002 Elsevier Science Ltd.
All rights reserved.
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1. Introduction
Insulin-like growth factor-I (IGF-I) is a polypep-
tide growth factor structurally related to insulin and
insulin-like growth factor-II, with relevant anabolic
effects on carbohydrate, protein and lipid metabolism
[1]. Circulating IGF-I is mainly synthesised in the
liver [2], and its production has been found to be
decreased in patients with chronic liver disease as
well as in experimental models of chronic liver injury
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[3–6]. Impaired production of IGF-I in advanced
liver disease has been suggested to contribute to mal-
nutrition in cirrhotic patients—reviewed in [3]. In
support of this notion, we have previously shown that
the administration of low doses of IGF-I can correct
the impaired intestinal absorption of nutrients in
CCl4-cirrhotic rats [7–9]. Furthermore, systemic ad-
ministration of IGF-I to rats with chronic liver disease
(CCl4-induced cirrhosis) resulted in improved liver
function and reduced collagen deposition [10]. The
hepatoprotective action of IGF-I in this experimental
model can be attributed in part to its ability to mod-
ulate the peroxidative liver damage elicited by CCl4
[10]. However, the molecular mechanisms behind this
in vivo effect of IGF-I are not completely known,
and can be further complicated by the fact that hep-
atic parenchymal cells express few IGF-I receptors
[11].
In order to gain more insight into the mechanisms
and signals behind the hepatoprotective action of
IGF-I, we have searched for genes whose expression
altered in the CCl4-cirrhotic rat liver is normalized
by IGF-I treatment. Our analysis employing the tech-
nique of differential display by means of polymerase
chain reaction (DD-PCR) [12], allowed us to identify
16 genes that were up- or down-regulated in the cirr-
hotic rat liver. IGF-I treatment partially normalized
the expression of eight of these genes. In addition,
this growth factor was capable of restoring global
DNA methylation at CpG sites, that is reduced in
the cirrhotic liver [13]. This latter effect of IGF-I,
together with the nature of some of the identified
genes, suggest that the hepatoprotective action of this
growth factor is mediated in part at the level of gene
expression.
2. Materials and methods
2.1. Materials
All chemicals were of the best quality commercially
available and otherwise stated they were purchased
from Sigma (St. Louis, MO, USA). Restriction en-
zymes were from Boehringer Mannheim (Mannheim,
Germany). [3H] dCTP (52 Ci/mmol) was from
Amersham.
2.2. Animals and treatments
All experimental procedures were performed in
conformity with our institution’s guidelines for the
use of laboratory animals. Cirrhosis was induced as
previously described [10]. Briefly, male Wistar rats
(3 weeks old, 130–150 g) were subjected to CCl4
inhalation (Merck, Darmstadt, Germany) twice a
week for 11 weeks with a progressively increasing
exposure time from 1 to 5 min. From that time until
the 30th week, rats were exposed to CCl4 once a
week for 3 min. During the whole period of cirrhosis
induction, animals received phenobarbital (Luminal,
Bayer, Leverkusen, Germany) in the drinking water
(400 mg/l). Rats were housed in cages placed in a
room with 12-h light-dark cycle and constant humi-
dity and temperature (20 ◦C). Both, food (standard
semipurified diet for rodents; B.K. Universal, Sant
Vicent dels Horts, Barcelona, Spain) and water were
given ad libitum. Healthy, age- and sex-matched con-
trol rats were maintained under the same conditions
but receiving neither CCl4 nor phenobarbital.
IGF-I or saline was administered the last three
weeks (27th–30th) of CCl4 exposure. Cirrhotic rats
were randomly assigned to receive either vehicle
(saline) (Group CI, n = 10) or recombinant human
IGF-I (Pharmacia-Upjohn, Sweden) (20g kg−1 per
day in two divided doses, subcutaneously) (Group
CI+ IGF-I, n = 10) for 3 weeks. Control rats (Group
CO, n = 10) received saline during the same period.
After 3 weeks of treatment, livers were removed,
weighted and snap frozen in liquid nitrogen.
2.3. RNA isolation and DD-PCR
Total RNA was extracted from frozen liver spec-
imens as previously described [14]. Twenty-five
milligrams of total RNA were incubated for 30 min
at 37 ◦C with 10 units of RNAse-free DNAse I
(Boehringer Mannheim, Mannheim, Germany) in 10
mmol/l Tris–HCl, pH 7.5, 10 mmol/l MgCl2, then
samples were phenol:chloroform extracted and etha-
nol precipitated in the presence of 0.3 mol/l sodium
acetate. RNA was redissolved in sterile nuclease-free
water.
DD-PCR was performed using fluorescent tag
labelled oligo (dT) anchored primers (FluoroDD,
Genomyx, Beckman Instruments, Fullerton, CA)
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with the Hieroglyph mRNA Profile Kit (Genomyx,
Beckman) following manufacturer’s instructions and
as previously described [15].
Following the DD-PCR, fluorescently-labelled
cDNA fragments were electrophoretically separated
on 4.5% polyacrylamide gels under denaturing condi-
tions in a Genomyx LR DNA Sequencer (Genomyx,
Beckman). DD-PCR products were visualized with a
Genomyx SC Fluorescent Imaging Scanner (Geno-
myx, Beckman). Bands of interest were excised
from the gel, and the gel slices were placed directly
into PCR tubes and reamplified using the Genomyx
Re-Amp Kit, following manufacturer’s instructions.
Reamplified cDNA fragments were cloned into
the plasmid vector pCR2:1-TOPO using TOPO-TA
Cloning Kit (Invitrogen, Leek, The Netherlands) and
sequenced in both directions using M13 reverse (−24)
primer and M1 forward (−20) primer. Nucleotide
sequence homology search analysis of the EMBL
[16] and GenBank [17] databases were performed
using the program FASTA [18].
2.4. Northern blot and RT-PCR analysis
Aliquots of 20g of total RNA were size-fractio-
nated by electrophoresis in a 1% agarose gel under
denaturing conditions. RNAs were then blotted and
fixed to Nytran membranes (Schleicher & Schuell,
Keene, NH, USA). Prehybridization and hybridiza-
tion were performed as described previously [14].
Probes used were the isolated clones from DD-PCR.
The rat IGF-I cDNA probe was the generous gift of
Dr. Peter S. Rotwein, Washington University School
of Medicine, St. Louis, MO, USA. The rat growth hor-
mone receptor (GHR) cDNA was cloned by RT-PCR,
specific primers were designed according to the pub-
lished sequence [19]. Equal loading of the gels was
assessed by hybridization with a probe specific for
the 18S rRNA. The probes were labelled with [-32P]
dCTP (3000 Ci/mmol) by random priming using
the Megaprime DNA labeling system (Amersham).
Specific activity was usually ∼5 × 108 cpm/g
of DNA. Quantitation was performed by scanning
densitometry of the X-ray films.
RT-PCR was performed to measure the expression
levels of hepatocyte nuclear factor-3 (HNF-3) in
total RNA samples from CO, CI and CI + IGF-I rat
livers. Aliquots of 2g of total RNA were reverse
transcribed using M-MLV Reverse Transcriptase
(Gibco Life Technologies, MD, USA) and subse-
quently amplified by PCR using the BioTaq DNA
Polymerase (Bioline, UK). The primers used were
deduced from the cDNA sequence of HNF-3 [20].
The 18S rRNA was simultaneously amplified using
the Alternate 18S Internal Standards primers set
(Ambion, TX, USA) and served as an internal loading
control. Reactions were resolved in a 2% agarose gel,
stained with ethidium bromide and quantitated using
the Molecular Analyst software (Bio-Rad, Hercules,
CA, USA). The 100-bp DNA Ladder molecular weight
standards from Gibco Life Technologies were used.
2.5. Immunoblot analysis
Frozen liver tissue samples were homogenized
in RIPA buffer (10 mM Tris–HCl, pH 7.4, 150 mM
NaCl, 1% Triton X-100, 1% sodium deoxycholate,
0.1% sodium dodecylsulfate, 0.1 mM phenyl-methyl-
sulfonyl fluoride, and 1 mM benzamidine). The homo-
genate was centrifuged for 30 min at 10,000 × g,
and supernatants collected. Equal amounts of protein
(20g) were subjected to 10% sodium dodecyl-
sulfate polyacrylamide gel electrophoresis, and
then electrophoretically transferred to nitrocellulose
membranes as described [15]. Antibodies for the
immunodetection of proliferating cell nuclear anti-
gen (PCNA) and CCAAT/enhancer binding protein 
(C/EBP), and a horseradish peroxidase-conjugated
secondary antibody were from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Where indicated,
equal loading of gels was assessed by probing
the membranes with an antibody specific for actin
(Calbiochem-Novabiochem, Darmstadt, Germany).
Blots were developed by enhanced chemoluminesce-
nce according to manufacturer’s instructions (DuPont,
Boston, MA, USA).
2.6. Global DNA methylation status
Genomic DNA was isolated from livers of CO, CI
and CI+ IGF-I rats as described previously [20]. The
DNA methylation at CpG sites assay was carried out
essentially as described [21]. This is a reverse assay,
in which higher levels of [3H] dCTP incorporation
into HpaII-digested genomic DNA indicate loss of
methyl groups at the CpG dinucleotides found in the
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restriction site of this methylation sensitive restriction
enzyme.
2.7. Statistics
Data are expressed as means ± S.E.M. Statistical
significance was estimated with Student’s t-test. A
P-value of <0.05 was considered significant.
3. Results
The biochemical and histological data, along with
the liver function tests of the animals used in this
study have been already described in our previous
publication [10]. At baseline, before the onset of IGF-I
treatment, groups CI and CI + IGF-I showed similar
serum levels of alanine aminotransferase, aspartate
aminotransferase, glucose, cholesterol, alkaline phos-
phatase, bilirubin, total protein and albumin, which
were all of them significantly abnormal as compared
to those in control rats. As previously mentioned,
IGF-I treatment resulted in a significant improvement
in serum albumin, total protein and clotting factors II,
VII and X levels, and partially prevented the increase
in liver peroxidation products and development of
fibrosis [10].
It has been reported that in chronic liver disease
circulating levels of IGF-I are reduced [3–6]. We have
Fig. 1. Expression of IGF-I mRNA in the liver of CO (control) and CI (cirrhotic) rats. (A) Northern blot analysis of IGF-I mRNA levels
in the liver of CO and CI rats. Hybridization with a cDNA probe specific for IGF-I yielded four bands of 7.0, 3.9, 1.8 and 1.1 kb.
Hybridization with a probe specific for the 18S rRNA is shown to demonstrate equal loading of the gel. A representative blot is shown.
(B) Quantitation of IGF-I mRNA levels in the liver of CO and CI rats. Values were normalized for loading by hybridization with a 18S
rRNA probe. Values are means± S.E.M. Asterisk (*) indicates P < 0.05 compared with CO value.
previously shown that in this experimental model of
CCl4-induced liver cirrhosis serum levels of IGF-I
were significantly decreased (35% of those found in
control animals) [4]. In order to evaluate if the hep-
atic expression of IGF-I gene was impaired in this
experimental model, liver IGF-I steady-state mRNA
levels were determined by Northern blot analysis
in CO and CI animals. As shown in Fig. 1A, and
in agreement with previous publications [5], after
hybridization with a cDNA probe for IGF-I four tran-
scripts of approximately 7.0, 3.9, 1.8 and 1.1–0.7 kb
were detected. Quantification of the 7.0 kb transcript,
and normalization of the values after hybridization
with a 18S rRNA, revealed that in cirrhotic animals
IGF-I expression was reduced by 50% as compared
to controls (Fig. 1B). In the cirrhotic animals treated
with IGF-I (CI + IGF-I group), the expression of
IGF-I gene was also reduced (data not shown).
IGF-I gene transcription is regulated by the inter-
action of hepatocyte nuclear factor-I, C/EBP, and
HNF-3 with its promoter and exon 1 [22–24].
Hepatocyte nuclear factor-I expression has been pre-
viously demonstrated to be down-regulated in the
cirrhotic liver [25], we have tested the expression of
C/EBP and HNF-3 in the liver of CO and CI ani-
mals. As shown in Fig. 2A, hepatic C/EBP protein
levels were markedly reduced in the CI animals, and
were not recovered after IGF-I treatment (data not
shown). A similar situation was observed for HNF-3,
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Fig. 2. Expression of C/EBP and HNF-3 in the liver of CO (control) and CI (cirrhotic) rats. (A) Western blot analysis of liver C/EBP
protein levels in CO and CI animals. Equal loading of the gel was assessed by probing the membranes with an antibody specific for
actin. A representative blot with two animals per group is shown. (B) HNF-3 expression in CO and CI rats was analyzed by quantitative
RT-PCR. 18S ribosomal RNA was used as internal control. Representative RT-PCR reactions for two controls (CO) and two cirrhotic (CI)
animals are shown. The left lane of the gel shows the molecular weight markers (MWM), the most intense band corresponds to 600 bp.
its expression was strongly reduced in the CI animals
(Fig. 2B), and was not restored upon IGF-I treatment
(data not shown).
In order to further characterise the biological
effects of IGF-I treatment, and the hepatocyte prolif-
erative activity in this model of cirrhosis, we assessed
the expression of PCNA in the liver of CO, CI and
CI+IGF-I rats. As shown in Fig. 3, PCNA levels were
slightly increased in the liver of CI rats, while they
were markedly enhanced in the IGF-I-treated animals.
Immunohistochemical analysis of these samples indi-
cated that PCNA expression was mainly localized in
the liver parenchymal cells (data not shown).
We next performed a DD-PCR analysis to search
for genes whose expression was altered in the cirrhotic
liver, and to identify novel target genes through which
IGF-I could mediate its hepatoprotective effects. As
indicated in Section 2, after excision from the gels
bands were amplified, cloned and used as probes for
Northern blotting. By this procedure, we have identi-
fied 16 genes whose steady-state mRNA levels were
Fig. 3. Expression of PCNA in the liver of control (CO), cirrhotic (CI) and IGF-I-treated cirrhotic rats (CI + IGF-I), as determined by
Western blotting. A sample of diethylnitrosamine-induced rat hepatocarcinoma tissue (HCC) was included as positive control. The image
shows a representative blot with two CO, three CI and three CI+ IGF-I liver samples. Equal loading of the gel was assessed by probing
the membranes with an antibody specific for actin.
changed in the liver of CI animals as compared to
CO or CO + IGF-I rats, their identity is summarized
in Table 1. The expression of 11 of these genes was
down-regulated in the cirrhotic liver (clones 1.B, 2.B,
12.A4, 1.3, 2.C1, 3.7, 12.1, 2.D4, 3.2, 3.B and 6.8),
four genes were induced (clones 8.A2, 9.A3, 4.A2 and
7.1) while the expression one gene (clone 4.2) was not
affected (Table 1). IGF-I treatment partially recovered
the expression of 5 of the 11 genes down-regulated in
the cirrhotic animals (clones 1.B, 12.A4, 3.B, 3.2 and
2.D4) (Table 1), in addition the expression of three out
of the four genes induced in the CI liver was also nor-
malized in part by IGF-I administration (clones 7.1,
4.A2 and 9.A3) (Table 1). The expression of clone 4.2
was not altered in the CI liver, however, it was signifi-
cantly induced in the IGF-I-treated animals (Table 1).
GHR expression has been shown to be reduced in
the liver of cirrhotic patients [26]. We have measured
the expression of GHR in our experimental model of
cirrhosis by Northern blotting. In agreement with the
situation found in humans, GHR mRNA levels were
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Table 1
Identity of the 16 clones isolated by DD-PCR screening performed in the livers of control, cirrhotic (CI) and IGF-I-treated cirrhotic rats
(CI + IGF-I). Indicated is also the level of expression (expressed as %) in relation to levels found in control animals (100%)a
Clone Identity/accession number CI expression levels
(% vs. CO ± S.E.M.)
CI + IGF-I expression levels
(% vs. CO ± S.E.M.)
6.8 Methionine adenosyltransferase/X15734 59.3 ± 13.5%∗ 43.2 ± 24.6%
3.7 Betaine-homocysteine methyltransferase/AF038870 43 ± 10%∗ 34 ± 8%
1.3 Apolipoprotein B100/X04714 48 ± 20∗ 30 ± 7%
2.C1 Apolipoprotein C2/Z15090 22 ± 6%∗ 13 ± 3.4%
3.2 Zn-alpha-2-glycoprotein/D21059 20 ± 5.6%∗ 56 ± 24%∗∗
4.A2 Carboxylesterase precursor/AB010570 1040 ± 333%∗ 555 ± 111%∗∗
2.B EST/AI101029 0.26 ± 0.2%∗ 6 ± 5%
4.2 EST/AA945168 73 ± 20% 190 ± 70%∗∗
8.A2 EST/AI030354 796 ± 217%∗ 666 ± 183%
7.1 Alpha-1-acid-glycoprotein/J00696 707 ± 200%∗ 309 ± 126%∗∗
9.A3 Chemokine 6Ckine/AF171085 100 ± 46.9%† 10 ± 4.1%††
12.1 Serine protease inhibitor 1/M15917 21 ± 7%∗ 32 ± 10.5%
2.D4 Serine protease inhibitor 2/X16358 32 ± 10%∗ 77 ± 21.5%∗∗
3.B Contrapsin-like protease inhibitor related protein/D00752 20.3 ± 9.2%∗ 96.7 ± 26.8%∗∗
12.A4 Alpha-1-antichymotrypsin precursor/AI583183 20 ± 8%∗ 125 ± 43%∗∗
1.B Alpha-2u-globulin/M24109 4 ± 2.3%∗ 43 ± 19%∗∗
a In the case of clone 9.A3 levels found in CI rats were arbitrarily given the value of 100%.
∗ P < 0.05 with respect control values.
∗∗ P < 0.05 with respect to CI values.
† P < 0.01 with respect to control values.
†† P < 0.01 with respect to CI values.
Fig. 4. GHR expression in the liver of control (CO), cirrhotic (CI)
and IGF-I-treated cirrhotic rats (CI + IGF-I) rats. GHR mRNA
levels were measured in the liver of CO, CI and CI+IGF-I animals
by Northern blotting. Blots were hybridized with a cDNA probe
for the GHR and with a probe for the 18S rRNA to assess for
equal loading of the gels. One asterisk (*) indicates P < 0.05
with respect to CO values, two asterisks (**) indicate P < 0.05
with respect to CI values. Data are means± S.E.M.
significantly decreased in the cirrhotic rat liver (Fig. 4).
Interestingly, IGF-I treatment resulted in the partial
recovery of GHR expression (Fig. 4).
Global DNA hypomethylation has been reported to
occur in the cirrhotic human liver and in other mod-
Fig. 5. IGF-I treatment restores the global levels of genomic
DNA methylation which are reduced in cirrhotic rats. CO, DNA
isolated from control rats; CI, DNA isolated form cirrhotic rats;
CI+IGF-I, DNA isolated from IGF-I-treated cirrhotic rats. Asterisk
(*) indicates P < 0.05 with respect to CO values.
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els of CCl4-induced cirrhosis in rats [13]. Changes in
this covalent modification of DNA can participate in
the alterations in gene expression observed in chronic
liver damage. We have tested the level of overall
methylation at CpG dinucleotides in the DNA from
CI animals as compared with CO rats. As shown in
Fig. 5, and in agreement with previous reports [13],
we observe a statistically significant reduction in the
level of overall DNA methylation in the cirrhotic
livers. Interestingly, DNA methylation levels were
recovered in the IGF-I-treated rats (Fig. 5).
4. Discussion
The growth hormone (GH)/IGF-I axis is markedly
altered in human and experimental liver cirrhosis and
in alcohol-induced liver disease [3–6,26–28]. Levels
of circulating IGF-I are decreased in such condition
while plasma GH is increased, however, there is a
reduction in high affinity GH receptors in the liver
parenchyma which leads to GH resistance in the liver
[3]. These alterations are likely to play a role in the
metabolic derangements associated with chronic liver
disease. In this regard, we have previously shown that
treatment with low doses of IGF-I is able to improve
the nutritional status, intestinal absorption, osteopenia,
hypogonadism and the impaired liver function in
rats with CCl4-induced cirrhosis [4,7–10]. However,
the mechanism of action of IGF-I regarding the
improvement of liver function is poorly understood.
In the present study, we have attempted to gain fur-
ther insight into the mechanisms behind the hepato-
protective action of this growth factor.
As previously mentioned, circulating IGF-I levels
are reduced in cirrhosis. We have previously shown
that this is also the case in our experimental model
of chronic CCl4-induced liver damage [4]. In agree-
ment with this observation, now we demonstrate that
IGF-I gene expression is impaired in the liver of CI
animals. IGF-I gene transcription is under the con-
trol of multiple liver-enriched transcription factors,
in particular Hepatocyte nuclear factor-I, C/EBP
and HNF-3 play a key role in IGF-I expression in
the liver [22–24]. Hepatocyte nuclear factor-I gene
expression is known to be reduced in the cirrhotic
liver [25]; now we observe that C/EBP and HNF-3
levels are also diminished in the livers of CI animals.
Impaired expression of these transcription factors in
the diseased liver probably compromises the syn-
thesis of IGF-I mRNA. These observations, together
with the reduced number of GH receptors in the liver,
may contribute to understand the impairment in IGF-I
production in cirrhosis.
Hepatocyte proliferation is an essential process in
the regenerative response observed in chronic liver
injury. This has been shown to occur in experimental
and human cirrhosis, where a positive correlation has
been found between the magnitude of this response
and the prognosis of the disease [29]. The prolifera-
tive activity of hepatocytes is commonly assayed by
determining the expression of PCNA, the auxiliary
protein of DNA polymerase- [30]. In agreement with
previous reports, we have observed that the expression
of PCNA was very low in the liver of control animals
and that it was increased in cirrhosis. Interestingly,
IGF-I treatment of cirrhotic animals further increased
the amount of this protein in the parenchymal cells.
This observation suggests that the hepatoprotective
action of IGF-I could be mediated in part by enhanc-
ing the endogenous regenerative response, aimed at
the restoration of functional liver mass.
The main objective of this work was the identifi-
cation of genes whose expression was altered in the
cirrhotic liver, and to assess the effect of in vivo IGF-I
treatment on their expression. This search was carried
out using the technique of DD-PCR [12,15], using
liver samples from control, cirrhotic and IGF-I-treated
cirrhotic rats. We have identified 16 genes whose
mRNA levels were either reduced or increased in
the liver of cirrhotic rats. IGF-I treatment restored,
to different degree, the expression of eight of these
genes. This observation, together with the enhance-
ment of PCNA expression, indicates that IGF-I is able
to modulate gene expression in the diseased liver.
“Although the contribution of non-parenchymal liver
cells cannot be excluded, clone 9.A3 is an example,
most of the identified genes are normally expressed,
or can be induced, in the hepatocyte”.
These 16 genes belonged to different categories
according to the function of the proteins they coded
for. There were metabolic genes involved in the
metabolism of methionine, such as methionine
adenosyltransferase [31] and betaine-homocysteine
methyltransferase [32], and in lipid and lipoprotein
metabolism such as the apolipoproteins B100 [33]
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and C2 [34], and Zn-alpha-2 glycoprotein [35]. The
expression of these genes was reduced in cirrhosis,
confirming our previous observations in the case of the
methionine metabolizing genes [36], and in agreement
with the profound alterations observed in lipopro-
tein metabolism in chronic liver disease [37]. Of the
five metabolic genes whose expression was found
to be reduced in the cirrhotic liver, IGF-I treatment
partially normalized the expression of Zn-alpha-2
glycoprotein. This is a poorly characterized secretory
protein with lipid-mobilizing properties, which in rats
is mainly expressed in the liver although it is widely
distributed in human tissues [35,38]. Other metabolic
gene whose expression was strongly induced in the
cirrhotic liver was the phenobarbital-inducible form
of the carboxylesterases, a large family of proteins
involved in drug metabolism [39]. This response was
consistent with the protocol used in this work for
the induction of cirrhosis, in which phenobarbital
is continuously administered in drinking water. The
observed partial reduction in the expression of this
xenobiotic-metabolizing gene by IGF-I could be attri-
buted in part to the more efficacious metabolism and
elimination of the barbituric due to the increased hep-
atic metabolic potential achieved by IGF-I treatment.
We isolated three cDNA clones (clones 2.B, 4.2
and 8.A2) that had no significant homology to any
published gene. There, however, existed two rat and
one mouse cDNA-expressed sequence tags that were
nearly identical to clones 4.2, 2.B and 8.A2, respec-
tively. The expression of clone 2.B was completely
lost in cirrhosis and IGF-I treatment was not able
to recover it. Conversely clone 8.A2 expression was
strongly induced and remained so in the IGF-I-treated
animals. The expression of clone 4.2 was not affected
in the cirrhotic liver, while IGF-I treatment induced
its expression by two-fold. These observations, toge-
ther with the strong induction of the inflammatory/
acute-phase protein alpha-1-acid glycoprotein [40] in
the cirrhotic rat, are interesting because they further
illustrate the fact that overall transcriptional activity of
the hepatocyte is not impaired in this model of chronic
liver damage, and that IGF-I treatment exerts specific
effects at the level of gene transcription in this organ.
The marked increase in alpha-1-acid glycoprotein
gene expression in the cirrhotic animals is probably
the combination of the stress response elicited by
CCl4, the direct effect of phenobarbital on its promoter
[40] and the down-regulation of GH receptors on the
damaged hepatocytes, since this hormone is a major
negative regulator of alpha-1-acid glycoprotein gene
transcription [40]. IGF-I administration partially
counteracted the induction of this gene, suggesting
that this growth factor is capable of modulating the
hepatic inflammatory response elicited in this exper-
imental model of liver damage. In line with this idea
is the fact that IGF-I almost totally suppressed the
strong induction in the expression of the chemokine
6Ckine observed in the cirrhotic liver. Indeed, clone
9.A3 was nearly identical to the mouse chemokine
6Ckine, a highly efficacious chemoattractant for lym-
phocytes [41], of which the rat homologue has not
been cloned yet. This chemokine, highly expressed in
high endothelial venules of lymph nodes and Peyer’s
patches, is expressed to a very low extent in the en-
dothelium of small lymphatic vessels in the liver [41].
Now, we describe its strong induction in chronic liver
damage and its modulation by IGF-I.
Another group of genes whose expression was
impaired in cirrhosis belonged to the large family of
secretory protease inhibitors. Among them, we have
identified: (i) the serine protease inhibitors 1 and 2,
two genes positively regulated by GH and whose tran-
scription is inhibited during inflammation [42,43]; (ii)
contrapsin-like protease inhibitor, a trypsin inhibitor
which is also negatively regulated by inflammation
[44] and (iii) alpha-1-antichymotrypsin, an acute
phase protein induced during inflammation with serine
protease inhibiting activity, whose expression is, how-
ever, reduced in our model of cirrhosis [45]. IGF-I
treatment restored the expression of all these protease
inhibitors with the exception of the serine protease
inhibitor 1. Although the actual roles of the plasma
protease inhibitors are not fully established, it is worth
mentioning that alpha-1-antichymotrypsin has been
recently described as a serum-borne anti-apoptotic
factor for vascular smooth muscle cells [46]. If such
activity is also exerted on hepatocytes, its positive
regulation by IGF-I could contribute to the hepato-
protective action of this growth factor.
One last gene identified in our analysis coded for
the highly abundant and male-specific liver protein
alpha-2u-globulin [47]. This gene, whose expression
was dramatically reduced in the cirrhotic liver, is the
subject of a complex hormonal regulation. Among
other factors its expression is positively regulated by
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GH and androgen [47]. Its impaired expression in
cirrhosis, thus could be explained in part by the GH
resistance that develops in this condition, and by the
fact that hypogonadism with low testosterone levels is
a frequent complication of cirrhosis, that also occurs
in our experimental model [4]. Since we have pre-
viously shown that IGF-I treatment reverts testicular
atrophy and improves free and total testosterone lev-
els in this same model of experimental cirrhosis [4],
this effect could be behind the partial restoration of
alpha-2u-globulin expression by IGF-I.
Although the beneficial effects of IGF-I treatment
in liver cirrhosis cannot be directly ascribed to the
improvement in the expression of one of the identi-
fied genes in particular, the fact that the expression
of several members of the protease inhibitors fam-
ily was partially restored could be of significance
regarding the therapeutic action of this growth
factor.
As previously mentioned, in patients with liver
cirrhosis the GH/IGF-I axis is altered. The circulating
levels of GH are markedly increased; however, the
expression of the GHR in the liver is impaired, mak-
ing this organ less sensitive to the hormone [26]. In
our experimental model, we also observe a reduction
in GHR mRNA levels in the liver of cirrhotic rats.
Interestingly, IGF-I treatment partially restored the
expression of GHR. Improved responses of the liver
parenchyma to GH could be behind the effects of IGF-I
treatment. This is supported by the fact that some
genes identified in our DD-PCR study are regulated by
GH. Such are the cases of alpha-2u-globulin and the
serine protease inhibitor 2, which are down-regulated
in cirrhosis and their expression is partially recovered
in the IGF-I-treated animals. The opposite situation
is also observed in the case of alpha-1-acid glyco-
protein, a gene negatively regulated by GH [40],
that is induced in cirrhosis and partially repressed in
response to IGF-I. Nevertheless, the partial restora-
tion of GHR levels is not sufficient to recover the
expression of other GH-responding genes, such as
the serine protease inhibitor 1 or IGF-I. As for IGF-I,
this may be explained by the marked impairment in
the expression of C/EBP and HNF-3 transcription
factors, which are essential for IGF-I gene expres-
sion [23,24], and are not recovered in the CI + IGF-I
animals.
These observations bring up the issue of the molec-
ular signals and pathways through which IGF-I exerts
its effects on the diseased liver. Its is known that
normal hepatocytes express few IGF-I receptors, and
that growth of normal liver is not affected by circu-
lating IGF-I [11,48,49]. In agreement with this, we
have not detected the expression of IGF-I receptors in
total liver homogenates of CO, CI nor healthy control
rats treated with IGF-I, when analysed by Western
blotting (data not shown). However, regenerating
rat hepatocytes have been described to possess such
receptors [48], thus it is possible that IGF-I could act
on the parenchymal cell fraction that proliferates in
the injured liver. In addition, IGF-I has been shown
to stimulate the production of hepatocyte growth fac-
tor, a potent mitogen and hepatoprotective agent, by
cultured hepatic stellate cells [50]. Taken together
our observations suggest that the combined actions of
direct IGF-I effects on the hepatocyte, together with
endocrine (GH, androgen) and paracrine (hepatocyte
growth factor) factors are likely to be behind the
beneficial effects of IGF-I on liver function.
In the present work, we have provided evidence
showing that IGF-I treatment of cirrhotic rats can
modulate the expression of certain genes, partially
restoring the normal gene expression profile found
in healthy animals. In addition, the ability of this
growth factor to revert the global hypomethylation
of genomic DNA observed in cirrhosis suggests that
IGF-I could, either directly or indirectly, have a broad
impact on gene expression in the diseased liver, given
the central role played by DNA methylation in the
control of gene activity.
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